Will NVIDIA Return to Its 52-Week High?
NVIDIA (NASDAQ:NVDA) has been among the best-performing investments of the…
Sell
34
BIO Quote, Financials, Valuation and Earnings
Last price:
$245.89
Seasonality move
:
7.01%
Day range:
$231.72 - $246.11
52-week range:
$215.38 - $387.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.70x
P/B ratio:
1.05x
Volume:
362.9K
Avg. volume:
433.4K
1-year change:
-21.19%
Market cap:
$6.9B
Revenue:
$2.6B
EPS (TTM):
-$65.04
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BIO
Bio-Rad Laboratories
|
$634.6M | $2.45 | -0.61% | -86.56% | $361.50 |
|
A
Agilent Technologies
|
$1.7B | $1.27 | 3.53% | 20.86% | $147.75 |
|
AVTR
Avantor
|
$1.7B | $0.26 | -4.32% | 159.99% | $23.09 |
|
BRKR
Bruker
|
$826.1M | $0.58 | 3.44% | 1050.16% | $63.21 |
|
RMD
ResMed
|
$1.3B | $2.45 | 7.21% | 15.65% | $267.15 |
|
RVTY
Revvity
|
$709M | $1.23 | 2.5% | 173.6% | $137.49 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BIO
Bio-Rad Laboratories
|
$245.80 | $361.50 | $6.9B | -- | $0.00 | 0% | 2.70x |
|
A
Agilent Technologies
|
$102.71 | $147.75 | $29.3B | 23.61x | $0.25 | 0.94% | 4.54x |
|
AVTR
Avantor
|
$15.22 | $23.09 | $10.4B | 14.63x | $0.00 | 0% | 1.53x |
|
BRKR
Bruker
|
$38.76 | $63.21 | $5.9B | 51.00x | $0.05 | 0.52% | 1.72x |
|
RMD
ResMed
|
$213.99 | $267.15 | $31.4B | 25.26x | $0.53 | 0.97% | 6.41x |
|
RVTY
Revvity
|
$94.86 | $137.49 | $11.4B | 42.92x | $0.07 | 0.3% | 4.23x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BIO
Bio-Rad Laboratories
|
15.46% | 1.613 | 13.06% | 4.53x |
|
A
Agilent Technologies
|
35.82% | 1.316 | 7.78% | 1.50x |
|
AVTR
Avantor
|
40.51% | 0.483 | 28.27% | 0.65x |
|
BRKR
Bruker
|
54.04% | 1.114 | 23.46% | 0.69x |
|
RMD
ResMed
|
11.35% | 0.237 | 2% | 1.74x |
|
RVTY
Revvity
|
29.13% | 0.972 | 23.4% | 2.75x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BIO
Bio-Rad Laboratories
|
$341.9M | $58.3M | -20.67% | -23.87% | -134.35% | $81.2M |
|
A
Agilent Technologies
|
$899M | $376M | 13.98% | 20.82% | 23.5% | $334M |
|
AVTR
Avantor
|
$562.9M | $191.5M | 6.78% | 12.92% | 37.3% | $145.8M |
|
BRKR
Bruker
|
$493.3M | $157M | 3.22% | 6.78% | 7.32% | $153.3M |
|
RMD
ResMed
|
$751.3M | $417.2M | 21.74% | 25.56% | 32.54% | $285.2M |
|
RVTY
Revvity
|
$412.3M | $124.5M | 2.37% | 3.45% | 16.09% | $149.8M |
Bio-Rad Laboratories vs. Competitors
-
Which has Higher Returns BIO or A?
Agilent Technologies has a net margin of -107.24% compared to Bio-Rad Laboratories's net margin of 18.92%. Bio-Rad Laboratories's return on equity of -23.87% beat Agilent Technologies's return on equity of 20.82%.
Company Gross Margin Earnings Per Share Invested Capital BIOBio-Rad Laboratories51.23% -$25.57 $7.8B AAgilent Technologies53.48% $1.11 $9.4B -
What do Analysts Say About BIO or A?
Bio-Rad Laboratories has a consensus price target of $361.50, signalling upside risk potential of 47.07%. On the other hand Agilent Technologies has an analysts' consensus of $147.75 which suggests that it could grow by 43.85%. Given that Bio-Rad Laboratories has higher upside potential than Agilent Technologies, analysts believe Bio-Rad Laboratories is more attractive than Agilent Technologies.
Company Buy Ratings Hold Ratings Sell Ratings BIOBio-Rad Laboratories3 2 0 AAgilent Technologies7 10 0 -
Is BIO or A More Risky?
Bio-Rad Laboratories has a beta of 1.119, which suggesting that the stock is 11.924% more volatile than S&P 500. In comparison Agilent Technologies has a beta of 1.189, suggesting its more volatile than the S&P 500 by 18.904%.
-
Which is a Better Dividend Stock BIO or A?
Bio-Rad Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agilent Technologies offers a yield of 0.94% to investors and pays a quarterly dividend of $0.25 per share. Bio-Rad Laboratories pays -- of its earnings as a dividend. Agilent Technologies pays out 21.26% of its earnings as a dividend. Agilent Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BIO or A?
Bio-Rad Laboratories quarterly revenues are $667.5M, which are smaller than Agilent Technologies quarterly revenues of $1.7B. Bio-Rad Laboratories's net income of -$715.8M is lower than Agilent Technologies's net income of $318M. Notably, Bio-Rad Laboratories's price-to-earnings ratio is -- while Agilent Technologies's PE ratio is 23.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories is 2.70x versus 4.54x for Agilent Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIOBio-Rad Laboratories2.70x -- $667.5M -$715.8M AAgilent Technologies4.54x 23.61x $1.7B $318M
-
Which has Higher Returns BIO or AVTR?
Avantor has a net margin of -107.24% compared to Bio-Rad Laboratories's net margin of 29.67%. Bio-Rad Laboratories's return on equity of -23.87% beat Avantor's return on equity of 12.92%.
Company Gross Margin Earnings Per Share Invested Capital BIOBio-Rad Laboratories51.23% -$25.57 $7.8B AVTRAvantor33.38% $0.73 $10B -
What do Analysts Say About BIO or AVTR?
Bio-Rad Laboratories has a consensus price target of $361.50, signalling upside risk potential of 47.07%. On the other hand Avantor has an analysts' consensus of $23.09 which suggests that it could grow by 51.71%. Given that Avantor has higher upside potential than Bio-Rad Laboratories, analysts believe Avantor is more attractive than Bio-Rad Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings BIOBio-Rad Laboratories3 2 0 AVTRAvantor8 8 0 -
Is BIO or AVTR More Risky?
Bio-Rad Laboratories has a beta of 1.119, which suggesting that the stock is 11.924% more volatile than S&P 500. In comparison Avantor has a beta of 1.236, suggesting its more volatile than the S&P 500 by 23.603%.
-
Which is a Better Dividend Stock BIO or AVTR?
Bio-Rad Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avantor offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Rad Laboratories pays -- of its earnings as a dividend. Avantor pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIO or AVTR?
Bio-Rad Laboratories quarterly revenues are $667.5M, which are smaller than Avantor quarterly revenues of $1.7B. Bio-Rad Laboratories's net income of -$715.8M is lower than Avantor's net income of $500.4M. Notably, Bio-Rad Laboratories's price-to-earnings ratio is -- while Avantor's PE ratio is 14.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories is 2.70x versus 1.53x for Avantor. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIOBio-Rad Laboratories2.70x -- $667.5M -$715.8M AVTRAvantor1.53x 14.63x $1.7B $500.4M
-
Which has Higher Returns BIO or BRKR?
Bruker has a net margin of -107.24% compared to Bio-Rad Laboratories's net margin of 1.4%. Bio-Rad Laboratories's return on equity of -23.87% beat Bruker's return on equity of 6.78%.
Company Gross Margin Earnings Per Share Invested Capital BIOBio-Rad Laboratories51.23% -$25.57 $7.8B BRKRBruker50.36% $0.09 $3.9B -
What do Analysts Say About BIO or BRKR?
Bio-Rad Laboratories has a consensus price target of $361.50, signalling upside risk potential of 47.07%. On the other hand Bruker has an analysts' consensus of $63.21 which suggests that it could grow by 63.07%. Given that Bruker has higher upside potential than Bio-Rad Laboratories, analysts believe Bruker is more attractive than Bio-Rad Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings BIOBio-Rad Laboratories3 2 0 BRKRBruker7 6 0 -
Is BIO or BRKR More Risky?
Bio-Rad Laboratories has a beta of 1.119, which suggesting that the stock is 11.924% more volatile than S&P 500. In comparison Bruker has a beta of 1.184, suggesting its more volatile than the S&P 500 by 18.426%.
-
Which is a Better Dividend Stock BIO or BRKR?
Bio-Rad Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker offers a yield of 0.52% to investors and pays a quarterly dividend of $0.05 per share. Bio-Rad Laboratories pays -- of its earnings as a dividend. Bruker pays out 26.7% of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BIO or BRKR?
Bio-Rad Laboratories quarterly revenues are $667.5M, which are smaller than Bruker quarterly revenues of $979.6M. Bio-Rad Laboratories's net income of -$715.8M is lower than Bruker's net income of $13.7M. Notably, Bio-Rad Laboratories's price-to-earnings ratio is -- while Bruker's PE ratio is 51.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories is 2.70x versus 1.72x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIOBio-Rad Laboratories2.70x -- $667.5M -$715.8M BRKRBruker1.72x 51.00x $979.6M $13.7M
-
Which has Higher Returns BIO or RMD?
ResMed has a net margin of -107.24% compared to Bio-Rad Laboratories's net margin of 26.88%. Bio-Rad Laboratories's return on equity of -23.87% beat ResMed's return on equity of 25.56%.
Company Gross Margin Earnings Per Share Invested Capital BIOBio-Rad Laboratories51.23% -$25.57 $7.8B RMDResMed58.6% $2.34 $5.9B -
What do Analysts Say About BIO or RMD?
Bio-Rad Laboratories has a consensus price target of $361.50, signalling upside risk potential of 47.07%. On the other hand ResMed has an analysts' consensus of $267.15 which suggests that it could grow by 24.85%. Given that Bio-Rad Laboratories has higher upside potential than ResMed, analysts believe Bio-Rad Laboratories is more attractive than ResMed.
Company Buy Ratings Hold Ratings Sell Ratings BIOBio-Rad Laboratories3 2 0 RMDResMed8 6 1 -
Is BIO or RMD More Risky?
Bio-Rad Laboratories has a beta of 1.119, which suggesting that the stock is 11.924% more volatile than S&P 500. In comparison ResMed has a beta of 0.755, suggesting its less volatile than the S&P 500 by 24.514%.
-
Which is a Better Dividend Stock BIO or RMD?
Bio-Rad Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.97% to investors and pays a quarterly dividend of $0.53 per share. Bio-Rad Laboratories pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BIO or RMD?
Bio-Rad Laboratories quarterly revenues are $667.5M, which are smaller than ResMed quarterly revenues of $1.3B. Bio-Rad Laboratories's net income of -$715.8M is lower than ResMed's net income of $344.6M. Notably, Bio-Rad Laboratories's price-to-earnings ratio is -- while ResMed's PE ratio is 25.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories is 2.70x versus 6.41x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIOBio-Rad Laboratories2.70x -- $667.5M -$715.8M RMDResMed6.41x 25.26x $1.3B $344.6M
-
Which has Higher Returns BIO or RVTY?
Revvity has a net margin of -107.24% compared to Bio-Rad Laboratories's net margin of 12.98%. Bio-Rad Laboratories's return on equity of -23.87% beat Revvity's return on equity of 3.45%.
Company Gross Margin Earnings Per Share Invested Capital BIOBio-Rad Laboratories51.23% -$25.57 $7.8B RVTYRevvity56.53% $0.78 $10.8B -
What do Analysts Say About BIO or RVTY?
Bio-Rad Laboratories has a consensus price target of $361.50, signalling upside risk potential of 47.07%. On the other hand Revvity has an analysts' consensus of $137.49 which suggests that it could grow by 44.94%. Given that Bio-Rad Laboratories has higher upside potential than Revvity, analysts believe Bio-Rad Laboratories is more attractive than Revvity.
Company Buy Ratings Hold Ratings Sell Ratings BIOBio-Rad Laboratories3 2 0 RVTYRevvity9 7 0 -
Is BIO or RVTY More Risky?
Bio-Rad Laboratories has a beta of 1.119, which suggesting that the stock is 11.924% more volatile than S&P 500. In comparison Revvity has a beta of 1.068, suggesting its more volatile than the S&P 500 by 6.796%.
-
Which is a Better Dividend Stock BIO or RVTY?
Bio-Rad Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revvity offers a yield of 0.3% to investors and pays a quarterly dividend of $0.07 per share. Bio-Rad Laboratories pays -- of its earnings as a dividend. Revvity pays out 12.74% of its earnings as a dividend. Revvity's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BIO or RVTY?
Bio-Rad Laboratories quarterly revenues are $667.5M, which are smaller than Revvity quarterly revenues of $729.4M. Bio-Rad Laboratories's net income of -$715.8M is lower than Revvity's net income of $94.6M. Notably, Bio-Rad Laboratories's price-to-earnings ratio is -- while Revvity's PE ratio is 42.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories is 2.70x versus 4.23x for Revvity. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIOBio-Rad Laboratories2.70x -- $667.5M -$715.8M RVTYRevvity4.23x 42.92x $729.4M $94.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will JP Morgan’s AI Advisor Be a Winner?
JPMorgan Chase is rolling out “JPM WealthAI for high-net-worth clients.…
Is Revolve Group Stock a Buy, Sell or Hold?
Recently, Revolve Group (NYSE:RVLV) management delivered some fairly positive business…
Stock Ideas
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Sell
50
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Buy
52
RGC alert for Apr 12
Regencell Bioscience Holdings [RGC] is up 29.14% over the past day.
Buy
52
SLP alert for Apr 12
Simulations Plus [SLP] is up 26.73% over the past day.
Buy
89
GDXU alert for Apr 12
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 15.9% over the past day.
